Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors

Investigational New Drugs

Volumn 31, Issue 1, 2013, Pages 77-84

  Annunziata, Christina M ^a   Kohn, Elise C ^a   Lorusso, Patricia ^b   Houston, Nicole D ^a   Coleman, Robert L ^c   Buzoianu, Manuela ^d   Robbie, Gabriel ^d   Lechleider, Robert ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d MEDIMMUNE   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Cancer therapy; Clinical trial; EphA2; MEDI 547; Relapsed refractory solid tumors

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; EPHRIN RECEPTOR A2 ANTIBODY; GLUCOSE; HEMOGLOBIN; IMMUNOGLOBULIN G1 ANTIBODY; MAGNESIUM; MEDI 547; MONOCLONAL ANTIBODY; SODIUM; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANGINA PECTORIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; COHORT ANALYSIS; CONJUNCTIVAL HEMORRHAGE; CONSTIPATION; DECREASED APPETITE; DEPRESSION; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; EYE PAIN; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE COUNT; LIVER DISEASE; LOW DRUG DOSE; MAGNESIUM BLOOD LEVEL; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; ONCOLOGICAL PARAMETERS; OPEN STUDY; ORAL BLEEDING; PAIN; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; REFRACTORY TUMOR; SIDE EFFECT; SODIUM BLOOD LEVEL; SOLID TUMOR; THROMBOCYTE COUNT; TREATMENT RESPONSE;

AGED; AMINOBENZOATES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; EPISTAXIS; FEMALE; HEMORRHAGE; HUMANS; MIDDLE AGED; NEOPLASMS; RECEPTOR, EPHA2;

EID: 84873084305     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9801-2     Document Type: Article

References (35)

1. Walker-Daniels J, Hess AR, Hendrix MJ, Kinch MS (2003) Differential regulation of EphA2 in normal and malignant cells. Am J Pathol 162:1037-1042
2. Zhang J, Hughes S (2006) Role of the ephrin and Eph receptor tyrosine kinase families in angiogenesis and development of the cardiovascular system. J Pathol 208:453-461
3. Lindberg RA, Hunter T (1990) cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. Mol Cell Biol 10:6316-6324
4. Kinch MS, Moore MB, Harpole DH Jr (2003) Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 9:613-618
5. Saito T, Masuda N, Miyazaki T, Kanoh K, Suzuki H, Shimura T, Asao T, Kuwano H (2004) Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis. Oncol Rep 11:605-611
6. Ireton RC, Chen J (2005) EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets 5:149-157
7. Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK (2009) EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst 101:1193-1205
8. Wykosky J, Gibo DM, Stanton C, Debinski W (2005) EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 3:541-551
9. Abraham S, Knapp DW, Cheng L, Snyder PW, Mittal SK, Bangari DS, Kinch M, Wu L, Dhariwal J, Mohammed SI (2006) Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res 12:353-360
10. Heroult M, Schaffner F, Augustin HG (2006) Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exp Cell Res 312:642-650
11. Hwu P, Sznol M, Kluger H, Rink L, Kim KB, Papadopoulos NE, Sanders D, Boasberg P, Ooi CE, Hamid O (2008) A phase I/II study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III/IV melanoma. J Clin Oncol 26:9029 (abstr)
12. Shao Z, Zhang WF, Chen XM, Shang ZJ (2008) Expression of EphA2 and VEGF in squamous cell carcinoma of the tongue: correlation with the angiogenesis and clinical outcome. Oral Oncol 44:1110-1117
13. Wang LF, Fokas E, Bieker M, Rose F, Rexin P, Zhu Y, Pagenstecher A, Engenhart-Cabillic R, An HX (2008) Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol Rep 19:151-156
14. Yuan WJ, Ge J, Chen ZK, Wu SB, Shen H, Yang P, Hu B, Zhang GW, Chen ZH (2009) Over-expression of EphA2 and EphrinA-1 in human gastric adenocarcinoma and its prognostic value for postoperative patients. Dig Dis Sci 54:2410-2417
15. Lee JW, Stone RL, Lee SJ, Nam EJ, Roh JW, Nick AM, Han HD, Shahzad MM, Kim HS, Mangala LS, Jennings NB, Mao S, Gooya J, Jackson D, Coleman RL, Sood AK (2010) EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res 16:2562-2570
16. Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Lin YG, Edwards C, Broaddus R, Coleman RL, Sood AK (2009) EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer 115:2684-2692
17. Miyazaki T, Kato H, Fukuchi M, Nakajima M, Kuwano H (2003) EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer 103:657-663
18. Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK (2004) EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 10:5145-5150
19. Wu D, Suo Z, Kristensen GB, Li S, Troen G, Holm R, Nesland JM (2004) Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma. Gynecol Oncol 94:312-319
20. Han L, Dong Z, Qiao Y, Kristensen GB, Holm R, Nesland JM, Suo Z (2005) The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol Oncol 99:278-286
21. Landen CN, Kinch MS, Sood AK (2005) EphA2 as a target for ovarian cancer therapy. Expert Opin Ther Targets 9:1179-1187
22. Jackson D, Gooya J, Mao S, Kinneer K, Xu L, Camara M, Fazenbaker C, Fleming R, Swamynathan S, Meyer D, Senter PD, Gao C, Wu H, Kinch M, Coats S, Kiener PA, Tice DA (2008) A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res 68:9367-9374
23. Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, Oflazoglu E, Toki BE, Sanderson RJ, Zabinski RF, Wahl AF, Senter PD (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 17:114-124
24. Younes A, Forero-Torres A, Bartlett N, Leonard JP, Rege B, Kennedy DA, Lorenz J, Sievers EL (2007) A novel antibody-drug conjugate, SGN-35 (anti-CD30-auristatin), induces objective responses in patients with relapsed or refractory Hodgkin lymphoma: preliminary results of a phase I tolerability study. Haematologica 92:64 (abstr P099bis)
25. Jackson D (2010) Early stage antibody drug conjugate development: preparations for the clinic. In: http://www.hansonwade.com/events/antibody-drug- conjugates/presentations/Dowdy-Jackson.pdf. Accessed December 13 2010
26. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
27. Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24:1633-1642
28. Swain SM, Arezzo JC (2008) Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 6:455-467
29. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812-1821
30. Naumovski L, Junutula JR (2010) Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther 12:248-257
31. Cai W, Ebrahimnejad A, Chen K, Cao Q, Li ZB, Tice DA, Chen X (2007) Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imaging 34:2024-2036
32. Tandon M, Vemula SV, Mittal SK (2011) Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets 15:31-51
33. Chang Q, Jorgensen C, Pawson T, Hedley DW (2008) Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer 99:1074-1082
34. Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK (2005) Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65:6910-6918
35. Gobin AM, Moon JJ, West JL (2008) EphrinA I-targeted nanoshells for photothermal ablation of prostate cancer cells. Int J Nanomedicine 3:351-358